Mirte Muller

1.8k total citations
29 papers, 893 citations indexed

About

Mirte Muller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mirte Muller has authored 29 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Mirte Muller's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Genomics and Diagnostics (6 papers). Mirte Muller is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Genomics and Diagnostics (6 papers). Mirte Muller collaborates with scholars based in Netherlands, Australia and United States. Mirte Muller's co-authors include Paul Baas, J.‐Y. Delattre, Khê Hoang‐Xuan, Robin Grant, Tjeerd J. Postma, Clare Moynihan, Neil K. Aaronson, Robert Huddart, Michel Lantéri‐Minet and Jerzy Hildebrand and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mirte Muller

28 papers receiving 877 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mirte Muller Netherlands 14 666 256 206 114 87 29 893
Ahmad Mosalaei Iran 15 172 0.3× 153 0.6× 84 0.4× 29 0.3× 22 0.3× 82 661
Koji Yoshino Japan 16 630 0.9× 190 0.7× 273 1.3× 15 0.1× 8 0.1× 66 1.1k
David A. Biddle United States 9 195 0.3× 41 0.2× 59 0.3× 130 1.1× 13 0.1× 13 513
Per Jönsson Sweden 18 361 0.5× 257 1.0× 26 0.1× 13 0.1× 49 0.6× 31 985
Radosław Mlak Poland 17 250 0.4× 286 1.1× 13 0.1× 56 0.5× 27 0.3× 109 892
Susan W. Pitman United States 11 222 0.3× 127 0.5× 40 0.2× 105 0.9× 11 0.1× 17 661
Terence T. Casey United States 13 189 0.3× 60 0.2× 230 1.1× 48 0.4× 7 0.1× 22 940
Junlong Li China 12 164 0.2× 35 0.1× 114 0.6× 28 0.2× 36 0.4× 43 578
Mels Hoogendoorn Netherlands 18 304 0.5× 60 0.2× 13 0.1× 299 2.6× 15 0.2× 75 887
Leonie Frauenfeld Germany 10 113 0.2× 165 0.6× 18 0.1× 43 0.4× 14 0.2× 26 517

Countries citing papers authored by Mirte Muller

Since Specialization
Citations

This map shows the geographic impact of Mirte Muller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirte Muller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirte Muller more than expected).

Fields of papers citing papers by Mirte Muller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirte Muller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirte Muller. The network helps show where Mirte Muller may publish in the future.

Co-authorship network of co-authors of Mirte Muller

This figure shows the co-authorship network connecting the top 25 collaborators of Mirte Muller. A scholar is included among the top collaborators of Mirte Muller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirte Muller. Mirte Muller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2024). Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PLoS ONE. 19(7). e0293707–e0293707. 2 indexed citations
2.
Muller, Mirte, Myron G. Best, Vincent van der Noort, et al.. (2023). Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. Tumor Biology. 46(s1). S327–S340. 1 indexed citations
3.
Vries, R. de, Niloufar Farzan, Frans H. de Jongh, et al.. (2023). Prospective Detection of Early Lung Cancer in Patients With COPD in Regular Care by Electronic Nose Analysis of Exhaled Breath. CHEST Journal. 164(5). 1315–1324. 26 indexed citations
4.
Muller, Mirte, Sjaak A. Burgers, Huub H. van Rossum, et al.. (2023). Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer. Tumor Biology. 46(s1). S269–S281. 4 indexed citations
5.
Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2022). PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research. 28(22). 4893–4906. 26 indexed citations
6.
Muller, Mirte, Sjaak A. Burgers, Huub H. van Rossum, et al.. (2022). Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. Heliyon. 8(10). e10932–e10932. 12 indexed citations
7.
Trebeschi, Stefano, Zuhir Bodalal, Thierry N. Boellaard, et al.. (2021). Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. Frontiers in Oncology. 11. 609054–609054. 37 indexed citations
8.
Verheijen, Remy B., Michel M. van den Heuvel, Mirte Muller, et al.. (2021). Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors. Cancer Chemotherapy and Pharmacology. 87(2). 269–276. 4 indexed citations
9.
Muller, Mirte, Rianne de Vries, Peter J. Sterk, et al.. (2021). eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. Lung Cancer. 160. 36–43. 19 indexed citations
10.
Muller, Mirte, Rom Langerak, Hendrik Koffijberg, et al.. (2021). Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy. Medical Decision Making. 41(6). 693–705. 1 indexed citations
11.
Muller, Mirte, Karlijn Hummelink, Daan P. Hurkmans, et al.. (2020). A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(19). 5188–5197. 17 indexed citations
12.
Baas, Paul, Robert D. Schouten, Mirte Muller, & Erik van Werkhoven. (2019). P2.04-83 Long-Term Follow-Up Compassionate Use Program Nivolumab in NSCLC. Journal of Thoracic Oncology. 14(10). S742–S742. 1 indexed citations
13.
Vries, R. de, Mirte Muller, Vincent van der Noort, et al.. (2019). Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. Annals of Oncology. 30(10). 1660–1666. 63 indexed citations
14.
Hummelink, Karlijn, Mirte Muller, Theodora C. Linders, et al.. (2019). Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Research. 5(1). 16–2019. 25 indexed citations
15.
Muller, Mirte, Catharina M. Korse, Daan van den Broek, et al.. (2018). Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot. Clinica Chimica Acta. 487. 6–14. 13 indexed citations
16.
Groeneveld, Geert H., Albert M. Vollaard, Mirte Muller, et al.. (2018). Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events. European Journal of Cancer. 104. 182–187. 47 indexed citations
17.
Schouten, Robert D., Mirte Muller, Cornedine J. de Gooijer, Paul Baas, & Michel M. van den Heuvel. (2017). Real life experience with nivolumab for the treatment of non-small cell lung carcinoma. Lung Cancer. 126. 210–216. 27 indexed citations
18.
Baas, Paul, Mirte Muller, Michel M. van den Heuvel, & Giulia Zago. (2016). New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics. Volume 10. 103–117. 21 indexed citations
19.
Postma, Tjeerd J., Neil K. Aaronson, Jan J. Heimans, et al.. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 41(8). 1135–1139. 431 indexed citations
20.
Zuetenhorst, Johanna M., R.A. Valdés Olmos, Mirte Muller, Cornelis A. Hoefnagel, & B.G. Taal. (2004). Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocrine Related Cancer. 11(3). 553–561. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmad Mosalaei Breakdown of academic impact, for papers by Koji Yoshino Breakdown of academic impact, for papers by David A. Biddle Breakdown of academic impact, for papers by Per Jönsson Breakdown of academic impact, for papers by Radosław Mlak Breakdown of academic impact, for papers by Susan W. Pitman Breakdown of academic impact, for papers by Terence T. Casey Breakdown of academic impact, for papers by Junlong Li Breakdown of academic impact, for papers by Mels Hoogendoorn Breakdown of academic impact, for papers by Leonie Frauenfeld
Rankless by CCL
2026